Molecular Pathology
Indica Labs, the leading provider of software for quantitative evaluation of digital pathology images, is pleased to announce selection of the HALO image analysis platform by the Netherlands Cancer Institute (NKI) for in situ analysis of...
Portland OR – September 29, 2017 – MolecularMD, a provider of molecular and tissue-based clinical trial assays and diagnostics for oncology based drug development programs, has announced a partnership agreement with Indica...
Promega Corporation intends to seek FDA approval and CE-IVD marking for a commercially available Microsatellite Instability (MSI) assay to assist oncologists and pathologists in determining colorectal cancer decisions. The current Promega...
Grail’s Billion Dollar Bet for the Perfect Cancer Test
- Advocacy
- Anatomic Pathology
- Business
- Clinical Laboratories
- Clinical Pathology
- Conferences
- Current Affairs
- Data Management
- Device Manufacturers
- Digital Pathology News
- Education
- General Healthcare News
- Genetics
- Histology
- Laboratory Informatics
- Laboratory Management & Operations
- Liquid Biopsy
- Medical Research
- Molecular Pathology
- Pathology News
- Science
- Tissue banking
Thought this was worth sharing from MIT Technology Review. After attending ASCO last week what I thought might happen a year or two again actually has. Pathologists no longer have to worry about stepping out from behind the paraffin curtain...
VisionGate, Inc. recently announced the appointment of Dr. David Wilbur as Medical Director of its Phoenix-based CLIA laboratory, VisionGate Biosignatures Laboratory (VBL). A world-renowned pathologist, Dr. Wilbur comes to VisionGate from...
Last month the FDA approved pembrolizumab (KEYTRUDA) for adult and pediatric patients with with metastatic or unresectable, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have...
